KRASG12R mutant-selective covalent inhibitor

privileged arginine-reactive functional group

from previously disclosed KRAS inhibitors

J. Am. Chem. Soc.

University of California San Francisco, San Francisco, CA

compound 3 chemical structure KRASG12R mutant-selective covalent inhibitor - University of California San Francisco, San Francisco, CA

Context. “Compound 3” (UCSF) is a covalent KRASG12R inhibitor used as a proof-of-concept for covalent arginine modification. KRAS is the first oncoprotein to be identified and is a well-known…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: